Helix BioPharma Corp. to Present CAR-T at AACR Annual

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
57
Helix BioPharma Corp. to Present CAR-T at AACR Annual Meeting 2017 in Washington, D.C.

TORONTO, ON--(Marketwired - Apr 3, 2017) - Helix BioPharma Corp. ( TSX : HBP ) ( FRANKFURT : HBP ) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its poster entitled: CAR-T cell harboring a camelid single domain antibody as a targeting agent to kill tumours expressing VEGFR2 has been accepted for presentation at the AACR Annual Meeting 2017 taking place on April 1 - 5, 2017 at the Walter E. Washington Convention Center Washington, D.C., USA.

This poster reports Helix's second study in applying camelid single domain antibody in making Chimeric Antigen Receptor T Cells ("CAR-T"). The poster describes preliminary data that explore the possibility of using this construct to target cancer cells that harbour the vascular epithelial growth factor receptor 2 ("VEGFR2") protein.

"We are pleased to share with the scientific community ongoing work in developing camelid and other antibodies for cell based therapy. We look forward to sharing more data on our CAR-T program in future publications and conference proceedings," said Dr. Heman Chao, Helix's newly appointed Chief Executive Officer and Chief Science Officer.

Presentation details are as follows:

Session Category: Clinical Research Session Title: Innate Effectors in Immunity to Cancer Session Date and Time: Tuesday Apr 4, 2017 8:00 AM - 12:00 PM Location: Convention Center, Halls A-C, Poster Section 30 Poster Board Number: 26

A copy of the poster will be made available on the Company's website.

About Helix BioPharma Corp. Helix BioPharma Corp. is an immune-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor ("CAR") based cell therapies. Helix is currently listed on the TSX and FRANKFURT under the symbol "HBP".

Cautionary Statements

This news release may contain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to the potential of using camelid single domain antibody in making CAR-T for solid tumour, or advancing any of the Company's CAR-T solid tumor candidate toward clinical testing, which may be identified by words including, without limitation, "will", "may", "expect", "estimate", "anticipate", "intend", "believe" or "continue" or the negative thereof or similar variations, are intended to provide information about management's current plans and expectations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated, no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include those described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.

Investor Relations Helix BioPharma Corp. 21 St. Clair Avenue East, Suite 1100 Toronto, Ontario, M4T 1L9 Tel: 416 925-3232 Fax: 416 925-1551 Email: ir@helixbiopharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 81

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 178

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 135

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
AI Echo Study Sharpens a Difficult HFpEF Diagnosis

Updated Category News Views 88

A single echo clip may be doing more useful work than plenty of flashy healthcare AI demos. The November 2026 Journal of Cardiac Failure focus issue puts a hard number on that possibility: pairing an AI read of a routine echocardiogram clip with the H?FPEF clinical score identified 78% of patients with hemodynamically confirmed HFpEF, versus 48% with the score alone. That...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 95

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 189

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading

Top 5 Most Recently Viewed Articles

Stocks Poised for Growth in Light of China's Rate Cuts

Updated Category News Views 81

Stocks Poised for Growth in Light of China's Rate Cuts As interest rates in China witness a significant reduction, investors' attention has naturally gravitated towards key Chinese stocks, which are experiencing renewed interest and rapid rallies. However, it may be wise to look beyond these familiar names and consider other companies that stand to benefit indirectly from...

Continue Reading
Vapotherm and Flight Medical Forge New Path for Ventilators

Updated Category News Views 264

Vapotherm and Flight Medical Forge New Path for Ventilators In a significant move for critical care, Vapotherm, Inc. has partnered with Flight Medical Innovations Ltd. to introduce the VentO2ux™ ventilator to hospitals throughout the United States. This collaboration marks a pivotal expansion for Vapotherm, known for its advanced respiratory support technologies, by...

Continue Reading
C1Risk Chosen to Enhance Government GRC Capabilities

Updated Category News Views 222

C1Risk Selected for Statewide Public Benefits System A major government organization has opted for C1Risk as its platform for Governance, Risk, and Compliance (GRC). This decision represents a crucial advancement in modernizing oversight within public benefits systems, highlighting the increasing necessity for efficient compliance automation for government entities....

Continue Reading
Exploring the Growth of the Self-Adhesive Tear Tapes Market

Updated Category News Views 151

Growth Potential of the Self-Adhesive Tear Tapes Market The self-adhesive tear tapes market is poised for substantial growth, projected to reach $281.9 million as demand for secure and convenient packaging continues to rise. This growth trajectory emphasizes not only the popularity of these tapes across various industries but also reflects ongoing advancements in...

Continue Reading
Shandong Radio and Television Station's Documentary Event Enriches Cultural Exchange

Updated Category News Views 154

Shandong Radio and Television Station's Documentary Event at a Prestigious University In an exciting collaboration, Shandong Radio and Television Station, along with its partner organizations, recently hosted a documentary promotion and screening event at a prominent university. This event provided an incredible opportunity for students and faculty to immerse themselves...

Continue Reading